ARS Pharmaceuticals, Inc. (SPRY)
- Previous Close
12.19 - Open
12.40 - Bid 13.52 x 200
- Ask 13.67 x 100
- Day's Range
12.40 - 13.77 - 52 Week Range
7.55 - 18.51 - Volume
2,214,797 - Avg. Volume
1,734,580 - Market Cap (intraday)
1.336B - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
-- - EPS (TTM)
-0.16 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.60
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
ars-pharma.comRecent News: SPRY
View MorePerformance Overview: SPRY
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPRY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPRY
View MoreValuation Measures
Market Cap
1.34B
Enterprise Value
1.06B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.39
Price/Book (mrq)
5.83
Enterprise Value/Revenue
10.91
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-16.11%
Return on Assets (ttm)
-6.10%
Return on Equity (ttm)
-6.91%
Revenue (ttm)
97.12M
Net Income Avi to Common (ttm)
-15.65M
Diluted EPS (ttm)
-0.16
Balance Sheet and Cash Flow
Total Cash (mrq)
275.73M
Total Debt/Equity (mrq)
30.33%
Levered Free Cash Flow (ttm)
-9.6M